title: Catecholamines modulate growth and differentiation of human preosteoclastic cells.
abstract: Using a clonal cell line of human osteoclast precursors (FLG 29.1 cells), that after treatment with 12-O-tetradecanoyl phorbol 13-acetate (TPA) show many functional characteristics of osteoclasts, we demonstrated that catecholamines act as inducers of osteoclast maturation in vitro and as stimulators of osteoclast activity via the binding to beta 2 adrenergic receptors. Scatchard analysis of 125I-labelled iodocyanopindolol to untreated (undifferentiated) or TPA-treated (differentiated) FLG 29.1 cells revealed the presence of a single high-affinity site with a Kd value around 24 pM and 8 pM respectively and with superimposable binding capacity (1.18 fmol/mg protein). Catecholamines increased in a dose-dependent fashion the intracellular cyclic AMP (cAMP) accumulation in both undifferentiated and TPA-treated FLG 29.1 cells. Pretreatment of untreated and TPA-treated FLG 29.1 cells with propranolol inhibited the catecholamine effect on cAMP accumulation, while pretreatment with clonidine had no effect. Catecholamines also reduced cell proliferation, increased tartrate-resistant acid phosphatase (TRAcP) activity, interleukin 6 (IL-6) production, multi-nuclearity and response to salmon calcitonin (sCT) in undifferentiated FLG 29.1 cells. In differentiated FLG 29.1 cells only IL-6 release was induced by catecholamine treatment. These findings support a potential role for catecholamines in modulating osteoclast differentiation and mature osteoclast activity.
authors.affiliation: Department of Clinical Physiopathology, University of Florence, Italy.
authors.forename: U
authors.initials: U
authors.lastname: Frediani
authors.forename: L
authors.initials: L
authors.lastname: Becherini
authors.forename: L
authors.initials: L
authors.lastname: Lasagni
authors.forename: A
authors.initials: A
authors.lastname: Tanini
authors.forename: M L
authors.initials: ML
authors.lastname: Brandi
mesh_terms: D018674:Adrenergic Antagonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000328:Adult; D002273:Carcinogens / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D000242:Cyclic AMP / Q000378:metabolism; D004837:Epinephrine / Q000494:pharmacology*; D005260:Female; D000091344:Filaggrin Proteins; D006801:Humans; D020120:Iodocyanopindolol; D009638:Norepinephrine / Q000494:pharmacology*; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010869:Pindolol / Q000031:analogs & derivatives / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
chemical_list: D018674:Adrenergic Antagonists; D000318:Adrenergic beta-Agonists; D002273:Carcinogens; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D020120:Iodocyanopindolol; D010869:Pindolol; D000242:Cyclic AMP; D013755:Tetradecanoylphorbol Acetate; D009638:Norepinephrine; D004837:Epinephrine